Madrigal Pharmaceuticals, Inc. (MDGL) 追踪市盈率为负值 -40.3, 表示公司目前在过去十二个月 (TTM) 基础上处于亏损状态。 前瞻市盈率 42.2 基于分析师预估，预计将恢复盈利。 追踪盈利收益率为 -2.48%, 前瞻盈利收益率 2.37%. PEG 0.54 (Peter Lynch 低估标准 ≤1.0).
本页证实的标准:
SharesGrow 综合评分： 54/100 其中 2/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -2.9 | 0.03 | 2.13 | 0.00 | - |
| 2017 | -36.1 | 0.72 | 6.17 | 0.00 | - |
| 2018 | -50.8 | 4.03 | 3.50 | 0.00 | - |
| 2019 | -16.7 | -0.15 | 3.37 | 0.00 | - |
| 2020 | -8.5 | -0.05 | 7.16 | 0.00 | - |
| 2021 | -5.8 | -0.49 | 7.15 | 0.00 | - |
| 2022 | -16.8 | -0.95 | 25.20 | 0.00 | - |
| 2023 | -11.6 | -0.72 | 10.67 | 0.00 | - |
| 2024 | -14.1 | -1.47 | 8.70 | 36.44 | - |
| 2025 | -45.3 | 1.10 | 21.68 | 13.63 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $-5.07 | $0.00 | $-26.39M | - |
| 2017 | $-2.54 | $0.00 | $-31.15M | - |
| 2018 | $-2.22 | $0.00 | $-32.81M | - |
| 2019 | $-4.73 | $0.00 | $-83.95M | - |
| 2020 | $-13.09 | $0.00 | $-202.24M | - |
| 2021 | $-14.63 | $0.00 | $-241.85M | - |
| 2022 | $-17.23 | $0.00 | $-295.35M | - |
| 2023 | $-19.99 | $0.00 | $-373.63M | - |
| 2024 | $-21.90 | $180.13M | $-465.89M | -258.6% |
| 2025 | $-12.85 | $958.4M | $-288.28M | -30.1% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $-4.49 | $-8.34 – $-0.52 | $1.48B | $1.42B – $1.51B | 9 |
| 2027 | $12.87 | $2.34 – $18.23 | $2.17B | $1.92B – $2.33B | 9 |
| 2028 | $31.37 | $16.07 – $49.15 | $2.99B | $2.99B – $2.99B | 11 |
| 2029 | $49.53 | $41.96 – $55.85 | $3.9B | $3.44B – $4.28B | 4 |
| 2030 | $70.33 | $59.58 – $79.31 | $4.87B | $4.29B – $5.34B | 4 |
